摘要
Parkinson's disease(PD), characterized by the loss of dopaminergic(DA) neurons in the substantia nigra pars compacta(SNpc) of the midbrain, is a prototype neurological disease that is suitable for cellular replacement therapy. Levodopa has been utilized to replace the insufficient dopamine released by degenerating DA neurons since the 1960s and it remains the cornerstone of PD treatment. However, as the disease progresses.
基金
the Singapore Ministry of Health's National Medical Research Council (Open Fund Large Collaborative Grant (MOH-000207)
Singapore Translational Research (STaR) Investigator A word (NMRC/STaR/0030/2018) to EKT,CS-IRG-NIG,OF-YIRG and TA award to BX) for their support。
